INTRODUCTION AND OBJECTIVES: Active surveillance (AS)
is a viable option for men with low risk prostate cancer. Perception of a physician's recommendation impacts the patient's final decision. We evaluated patient factors associated with the perceived suggestion of treatment.
METHODS: Since 2011, men with Gleason grade group 1 (GG1) prostate cancer were enrolled in a prospective study to evaluate psychologic factors associated with AS decision making for patients and their spouses. Data collection continues, preliminary results are reported. Patients completed a survey evaluating various psychologic measures prior to making their final decision (baseline) and during follow-up after choosing treatment or AS. We studied the association between patient characteristics and baseline psychologic measures with the patient's perceived suggestion of treatment. We measured the patient's perceived suggestion of treatment based on a previously developed scale that distinguishes immediate treatment versus active surveillance. A perceived neutral suggestion of treatment would correlate to values close to zero and strong perceptions of either AS or immediate treatment would be reported as values of -5 and 5, respectively.
RESULTS: Between 2011 and 2018, 189 men with GG1 were enrolled in the study. 174 men had completed the baseline survey and made a treatment decision. 102 men were classified with very low risk prostate cancer (<3 cores, <50% in any core) and 51 were classified as low risk. 31(18%) selected immediate treatment. Overall, 38(22%) perceived the physician's suggestion to treatment. On univariate analysis, only younger age was associated with the perceived suggestion of immediate treatment (p[0.02). We did not find a statistically significant association with patient characteristics including education level and ethnicity or baseline psychologic measures including anxiety (Memorial Anxiety Scale for Prostate Cancer), mood (Profile of Mood Status scale), and sense of optimism (Life Orientation Test-Revised). We did not find statistically significant differences in the distributions of patient perceptions of treatment among surgeons (n[7). The results did not change when we assessed the outcome as a strong perceived suggestion to treatment.
CONCLUSIONS: Despite a standardized recommendation for AS, we identified varied perceptions of patients' assessment of surgeon's suggestion to immediate treatment vs AS. Physicians who recommend AS should be aware that a significant proportion of patients, especially younger men, perceive their suggestion to immediate treatment.
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MP48-07 THIRTY-YEAR NATIONWIDE POPULATION-BASED FOLLOW-UP OF MEN ON ACTIVE SURVEILLANCE FOR PROSTATE CANCER: WHO BENEFITS THE MOST? A STATE-TRANSITION ANALYSIS
Eugenio Ventimiglia*, Milan, Italy; Mieke Van Hemelrijck, London, United Kingdom; Lars Lindhagen, P€ ar Stattin, Uppsala, Sweden; Hans Garmo, London, United Kingdom INTRODUCTION AND OBJECTIVES: Due to limited follow-up time of active surveillance (AS) series, the safety of AS is still questioned. We present a state-transition model of men with prostate cancer (PCa) primarily managed with AS with a 30-year follow-up.
METHODS: We created and applied a state-transition model for treatment trajectories with estimated states, state transitions, and transition probabilities in Prostate Cancer data Base of Sweden (PCBaSeTraject), using nationwide population-based data from 23,649 men diagnosed with PCa and managed with deferred treatment. Discrete time steps of four weeks were used to capture all transitions (PCBaSeSim) until death from PCa or other causes. We then simulated 100,000 men per each combination of age at diagnosis, range: 55-70 years, Charlson comorbidity index (CCI) 0, 1, and 2, modified NCCN PCa risk classification, very low-risk, low-risk, intermediate-risk with Gleason grade group 2, and PSA levels (range 1-10 ng/ml) with a follow-up of 30 years. PCa and other causes for death at age 85 were estimated for every combination, as well as the proportion of time without active PCa treatment (i.e. time on AS and post-AS watchful waiting/remaining lifetime). We then assessed tradeoffs in terms of time without active PCa treatment from date of diagnosis until date of death or age 85 vs risk of PCa death.
RESULTS: Among healthy men (CCI[0), the proportion who died of PCa death at age 85 among men diagnosed at age 70 was 4% for very low-risk PCa, 6% for low-risk and 7% for intermediate-risk. For men diagnosed at age 55, the corresponding percentages were 11%, 14%, and 16%. The mean proportion of time spent without active PCa treatment for men diagnosed at age 55 was 13/25 years (51%) for very low-risk PCa, 10/25 years (41%) for low-risk PCa, and 9/25 (35%) for intermediate-risk PCa; for men at age 70, the corresponding percentages were 10/13 years (78%), 9/13 years (70%), and 8/13 years (63%). Men with intermediate-risk PCa diagnosed below 60 years had little benefit in terms of time without active PCa treatment (35-39%) considering their high risk of PCa death (13-16%), whereas men older than 65 years with low-risk PCa had a larger benefit in terms of both longer time without active PCa treatment (53-70%) and lower risk of PCa death (6-8%).
CONCLUSIONS: In our state transition model with 30-year follow-up, AS was a safe treatment strategy in healthy men above 65 years with low-risk PCa.
Source of Funding: none
MP48-08 THE LONG-TERM OUTCOMES OF GRADE GROUPS 2 AND 3 PROSTATE CANCER MANAGED BY ACTIVE SURVEILLANCE: RESULTS FROM A LARGE POPULATION-BASED COHORT
Patrick Richard*, Saint-denis de-Brampton, Qc, Canada; Narhari Timishina, Maria Komisarenko, Lisa Martin, Ardalan Ahmad, Shabbir Alibhai, Robert Hamilton, Girish Kulkarni, Antonio finelli, Toronto, Canada INTRODUCTION AND OBJECTIVES: Prostate cancer is the most common solid organ cancer among North American men. Traditionally, men diagnosed with prostate cancer were offered treatments in the form of radical prostatectomy, external-beam radiotherapy or brachytherapy. However, natural history studies have shown that only a minority of those with low or intermediate risk disease will develop metastases and/or succumb to the cancer. Thus, active surveillance has become an accepted strategy for low-risk, but debated as to its application in intermediate-risk prostate cancer. Unfortunately, most reports of intermediate-risk prostate cancer managed by active surveillance generally lack long-term follow-up and include small numbers of patients. Thus, the objective of this population-based study was to report the long-term outcomes of men diagnosed with Grade Groups 2 and 3 prostate cancer who were managed expectantly.
METHODS: Using administrative datasets and pathology reports, we identified all men who were diagnosed with Grade Groups 2 and 3 prostate cancer and managed expectantly between 2002 and 2011 in Ontario, Canada. The overall survival, cancer-specific survival and treatment-free survival were estimated using cumulative incidence function methods while their associated factors were estimated multivariable Cox regression models.
RESULTS: We identified 926 men with GG2 or GG3 PCa that were managed expectantly (active surveillance (n[374) or watchful waiting (n[552)). The 8-year cancer-specific survival was 94% and 89% for the active surveillance and watchful waiting cohorts, respectively. Among men managed by active surveillance, 266 (71%) Vol. 201, No. 4S, Supplement, Sunday, May 5, 2019 THE JOURNAL OF UROLOGY Ò e699
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